Potential protective effects of telmisartan on renal function deterioration

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 4, 2006, Pages 185-191

  Remuzzi, Andrea ^a,b   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Angiotensen II peroxisome activated receptor gamma; Angiotensin receptor antagonist; Angiotensin converting enzyme inhibitors; Insulin resistance renal diseases; Metabolic syndrome; Renoprotection

Indexed keywords

ADENOSINE RECEPTOR; ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR; ENALAPRIL; ENDOTHELIN RECEPTOR; EPROSARTAN; GLITAZONE DERIVATIVE; GLUCOSE TRANSPORTER 4; IRBESARTAN; LISINOPRIL; LOSARTAN; NATEGLINIDE; OLMESARTAN; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RAMIPRIL; TELMISARTAN; UNINDEXED DRUG; VALSARTAN;

ADIPOCYTE; ANTIHYPERTENSIVE ACTIVITY; BINDING AFFINITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; FLUID RETENTION; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; META ANALYSIS; METABOLIC SYNDROME X; MONOTHERAPY; NONHUMAN; PROTEIN EXPRESSION; REMISSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; DIABETES MELLITUS, TYPE 2; HUMANS; KIDNEY DISEASES; METABOLIC SYNDROME X;

EID: 33847729477     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.036     Document Type: Review

References (42)

1. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985;249:F324-F337.
2. Remuzzi A, Puntorieri S, Alfano M et al. Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury. Laboratory Investigation 1992;67:572-9.
3. Benigni A, Zoja C, Remuzzi G. The renal toxicity of sustained glomerular protein traffic. Laboratory Investigation 1995;73:461-8.
4. Benigni A, Remuzzi G. Glomerular protein trafficking and progression of renal disease to terminal uremia. Semin Nephrol 1996;16:151-9.
5. Remuzzi A, Gagliardim E, Donadoni C et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002;62:885-94.
6. Remuzzi G, Remuzzi A. Is regression of chronic nephropathies a therapeutic target? J Am Soc Nephrol 2005;16:840-2.
7. Remuzzi A, Gagliardini E, Sangalli F et al. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 2006; 69:1124-30.
8. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001;61:1501-29.
9. Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005;25:41-6.
10. Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006;66:51-83.
11. Redon J, Luque-Otero M, Martell N, Chaves FJ. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 2005; 5:14-20.
12. 1, receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens 1999;17:293-302.
13. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43:993-1002.
14. Schupp M, Janke J, Clasen R et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-7.
15. Sharma AM. Telmisartan: the ACE of ARBs? Hypertension 2006;47:822-3.
16. Amerena J, Pappas S, Ouellet JP et al. ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. J Int Med Res 2002;30:543-52.
17. Ragot S, Ezzaher A, Meunier A et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002;16:865-73.
18. Williams B, Gosse P, Lowe L, Harper R. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006;24:193-200.
19. Ingino C, Farsang C, Laucevicius A, Bergovec M. An open-label study investigating the efficacy and safety of 12-96 weeks of telmisartan treatment in patients with hypertension. J Int Med Res 2003;31:561-74.
20. Janke J, Engeli S, Gorzelmak K et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002;51:1699-707.
21. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004;44:12-19.
22. Engeli S, Bohnke J, Gorzelniak K et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45:356-62.
23. Tang WH. Do thiazolidinediones cause heart failure? A critical review. Cleve Clin J Med 2006;73:390-7.
24. Irons BK, Greene RS, Mazzolini TA et al. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy 2006;26:168-81.
25. Oberfield JL, Collins JL, Holmes CP et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 1999;96:6102-06.
26. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50.
27. Sugimoto K, Qi NR, Kazdova L et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006;47:1003-09.
28. Ouchi N, Kihara S, Funahashi T et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-4.
29. Arita Y, Kihara S, Ouchi N et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002;105:2893-8.
30. Matsuda M, Shimomura I, Sata M et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002;277:37487-91.
31. Wassmann S, Hilgers S, Laufs U et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002;22:1208-12.
32. Wassman S, Czech T, van Eickels M et al. inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein e/ anglotensin II type 1a receptor double-knockout mice. Circulation 2004;110:3062-7.
33. Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens 2005;23:97-104.
34. Fujimoto M, Masuzaki H, Tanaka T et al. An angiotensin II AT1-receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 2004;576:492-7.
35. Fogari R, Lazzari P, Zoppi A. Effect of telmisartan losartan and lisinopril on insulin sensitivity in hypertensive patients with and without insulin resistance. Eur Heart J 2004;25:78.
36. Koulouris S, Symeonides P, Triantafyllou K et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 2005;95:1386-8.
37. Remuzzi A, Perico N, Sangalli F et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephrology. Am J Physiol 1999;276:F457-66.
38. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
39. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev: CD004136, 2005.
40. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-08.
41. Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol 2006;17:S132-S135.
42. Sugiyama H, Kobayashi M, Wang DH et al. Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant 2005;20:2670-80.